AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05100251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WBC100 QOD
Description: The first stage: single dose escalation according to classic 3+3 dose escalation method. 7 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QOD. The second dose group is 1mg QOD. The third dose group is 1.5 mg QOD. The fourth dose group is 2.0 mg QOD. The fifth dose group is 2.5 mg QOD. The sixth dose group is 3.0 mg QOD. The seven dose group is 3.5 mg QOD. In each dose group, patients take WBC100 once on cycle 0. After a washout period of 2 days, patents start subsequent 4 weeks cycles until progression disease or intolerable toxicity. In each cycle, patient was on WBC100 every for 3 weeks and off for 1 week.~The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type
Study NCT05100251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WBC100 QD
Description: The first stage: single dose escalation according to classic 3+3 dose escalation method. 6 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. The fifth dose group is 2.5 mg QD. The sixth dose group is 3.0 mg QD. In each dose group, the patient was on WBC100 until progression disease or intolerable toxicity. Patient was on WBC100 every for for 3 consecutive weeks (with QD dosing for the first 5 days of each week followed by a 2-day rest), followed by a 1-week rest period, with a 4 weeks as one cycle. The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type
Study NCT05100251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WBC100 BID
Description: The first stage: single dose escalation according to classic 3+3 dose escalation method. 4 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. In each dose group, the patient was on WBC100 until progression disease or intolerable toxicity. Patient was on WBC100 every for 2 consecutive weeks, followed by a 1-week rest period, with 3 weeks as one treatment cycle; The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type
Study NCT06484985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT-1003
Description: AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
Study NCT05368558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Oral Capsule
Study NCT05368558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cariprazine
Description: Oral Capsule
Study NCT05368558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study NCT05070390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Chloride
Description: 10 mg capsule administered orally
Study NCT06285240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1167
Description: 1 mg and 5 mg oral capsules
Study NCT06285240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg oral tablets
Study NCT06285240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: 10 mg oral tablets
Study NCT06285240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-1167 matching placebo administered oral capsules
Study NCT05254158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174 0833
Description: Participants will either get a single dose of 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833, administered subcutaneously (s.c., under the skin)
Study NCT04766229 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Citalopram +/- Gabapentin + Sleepio + support person
Description: All participants will receive citalopram and/or gabapentin to manage vasomotor symptoms of menopause and will get access to digital CBT for insomnia and be asked to identify a support person
Study NCT05618028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-525
Description: Oral; Tablet
Study NCT05534971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous catheter insertion
Description: The clinical team will use the technique to establish central venous access
Study NCT05534971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central venous catheter insertion
Description: The clinical team will use the technique to establish central venous access
Study NCT04720508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample collection.
Description: venipuncture procedure
Study NCT04835805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belvarafenib
Description: Twice daily (BID), continuous dosing
Study NCT04835805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Once daily (QD) or three times weekly (TIW) for 21 days, 7 days off
Study NCT06512441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B6 Tablets
Description: The experimental group was given a Vitamin B6 tablet（10mg/tablet）once a day for 3weeks, besides of the standard IBD treatment.
Study NCT06512441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B6 Tablets
Description: The experimental group was given a Vitamin B6 tablet（10mg/tablet）once a day for 3weeks, besides of the standard IBD treatment.
Study NCT06512441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The control group was given a placebo tablet on the same type once a day for 3weeks, besides of the standard IBD treatment.
Study NCT06512441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group was given a placebo tablet on the same type once a day for 3weeks, besides of the standard IBD treatment.
Study NCT06381518 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Switch to SC CT-P13.
Description: all patients in the study will switch from IFX to SC CT-P13
Study NCT05804305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol is a prostaglandin E1 analogue
Study NCT05804305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contained substance that has no therapeutic value.
Study NCT04835805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Once every 4 weeks (Q4W)
Study NCT04802967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen Lysine Salt combined with Gabapentin
Description: KLS-GABA (80 mg-34 mg) in Part A and KLS-GABA (40 mg-17 mg or 80 mg-34 mg or 160 mg-68 mg) in Part B
Study NCT04802967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen Lysine Salt
Description: KLS (80 mg) alone in each treatment period in Part A and KLS alone (40 mg, 80 mg, or 160 mg) in Part B
Study NCT04514497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT04514497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04514497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04514497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib
Description: Given PO
Study NCT06377475 — intervention group
Intervention type: PROCEDURE
Intervention: Questionnaire
Description: The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.
Study NCT05037032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Pill
Description: 50 mg PO one-time only
Study NCT05037032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for naltrexone
Study NCT06331754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology-enabled blood pressure management
Description: The intervention will consist of a technology-enabled remote hypertension management program.
Study NCT04697472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFT System
Description: The LIFT System delivers the ARC Therapy to improve upper extremity function in individuals with tetraplegia.
Study NCT05670964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connecting valve system
Description: UPLUG Port (changed every 29 days) and UPLUG Disposable (changed at every dialysis session) ensure the connection between a regular haemodialysis catheter and an extracorporeal circuit, and proceed to different steps of haemodialysis session without handling the Luer-Lock connectors of the haemodialysis catheter
Study NCT05670964 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Central haemodialysis Venous Catheter
Description: Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session
Study NCT04514497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT04514497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04514497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT05919745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: Preoperative delivery of ibuprofen per os.
Study NCT05919745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preoperative delivery of placebo per os.
Study NCT05919745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Both groups will be given rescue medication in the form of 1,000 mg tabs of acetaminophen every 6 hours per os as needed for pain (maximum allowed daily dose 4,000 mg per FDA) and will be allowed to receive ibuprofen or other analgesic medication as needed if pain is not controlled by acetaminophen alone. The subjects will receive the rescue medication pills at the end of the surgical appointment.
Study NCT05325788 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: e-Covery
Description: Through the e-Covery app, participants will receive place-specific messages, sent when participants pass locations identified as triggers.
Study NCT05325788 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparator Condition
Description: Through the e-Covery app, participants will receive a single general message sent daily in the morning.
Study NCT04731181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile application (little lovely dentist).
Description: mobile application
Study NCT05497154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Arm
Description: The training will be composed of 4 separate training sessions provided every 2 - 4 weeks. During the 1st session (45 minutes), the investigators will educate the physical therapist about the different categories of opioid use including opioid misuse (OM) and the risks associated with OM as well as training to engage the patient in a conversation about opioid use. The 2nd and 3rd sessions (30 minutes each) involve training in procedures to screen and assess patients at risk for OM, respectively. The 4th session (30 minutes) involves training in procedures to refer patients to a specialist or a primary care provider for further treatment if OM is suspected.
Study NCT05427708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive Exposure
Description: See: Arm/group descriptions
Study NCT05427708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnometry-Guided Respiratory Intervention
Description: See: Arm/group descriptions
Study NCT05427708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-Education
Description: See: Arm/group descriptions
Study NCT05919745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Both groups will be given rescue medication in the form of 1,000 mg tabs of acetaminophen every 6 hours per os as needed for pain (maximum allowed daily dose 4,000 mg per FDA) and will be allowed to receive ibuprofen or other analgesic medication as needed if pain is not controlled by acetaminophen alone. The subjects will receive the rescue medication pills at the end of the surgical appointment.
Study NCT05139758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biodex Balane System
Description: The Biodex balance system will be used for the assessment of static and dynamic balance of all children in the current study.
Study NCT05103709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MULTI-FORTIFIED
Description: Treatment with multifortified bread for 120 days
Study NCT04802967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 300 mg
Study NCT04802967 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules to maintain the blind
Study NCT05103709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FORTIFIED
Description: Treatment with standard bread, fortified according to current Peruvian guidelines for 120 days
Study NCT05670964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Central haemodialysis Venous Catheter
Description: Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session
Study NCT06396507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin Solution
Description: permethrin 5 % solution
Study NCT06396507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin Solution
Description: permethrin 5 % solution
Study NCT06396507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur
Description: Sulfur 10%+ vaseline 90 % ointment
Study NCT06517615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Visit Supported Nursing Training Program
Description: Individualized Nurse Education Program with Home Visit Support (• Walking and exercise programs, Disease self-management training for those with chronic diseases, techniques and practices that facilitate medication compliance, vital sign monitoring, • • • Nutrition charts and follow-ups, food characteristics information and weight tracking, cooking activities in the kitchen,• Helping to create family and friend systems, creating neighbor communication mechanisms
Study NCT04388280 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiography
Description: Functional assessment of coronary artery disease
Study NCT04768634 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Provocative electrophysiology study
Description: Provocative electrophysiology testing will be performed at the bedside using the temporary pacing wires placed at the time of surgery.
Study NCT06315998 — intervention group
Intervention type: DEVICE
Intervention: Magnetocardiography
Description: Magnetocardiography
Study NCT04388280 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT angiography
Description: Anatomical assessment of coronary artery disease
Study NCT05687695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: backward walking program
Description: six weeks of backward walking program at self selected speed for 30 minutes 3 times per week
Study NCT05687695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: core training
Description: six weeks of core training program including curl up, lateral plank on both sides, bird dog exercises done 3 times per week
Study NCT06288672 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: True avoidance diet
Description: Food patch test-directed avoidance diet for 16 weeks where participant avoids avoid eating the food(s) to which they are allergic
Study NCT06288672 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham avoidance diet
Description: Avoidance diet for 16 weeks of randomly selected foods to which the patch testing did not show an allergy
Study NCT05264571 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: calscreener
Description: The calscreener (SYMCEL®) is a new diagnostic tool to rapidly identify the presence of pathogens in biological samples based on micrometabolic activity detection. All living cells produce heat by the chemical and physical processes of life; by monitoring the heat flow over time (J/s, W) a significant amount of information can be obtained regarding the biological system.
Study NCT05264571 — intervention group
Intervention type: OTHER
Intervention: Metabolic profile
Description: The cal screener allows the measure of metabolic activity of pathogens directly from a sample (here, the peritoneal fluid).~The heat production will be compared between peritoneal fluid, with or without addition of bacteria
Study NCT05264571 — intervention group
Intervention type: OTHER
Intervention: optical microscopy
Description: To explain the metabolic activity, growth and yeast-to-hyphae transition will be analysed using optical microscopy and conventional culture
Study NCT05264571 — intervention group
Intervention type: OTHER
Intervention: RTqPCR
Description: To explain the metabolic activity, level of expression of 5 Candida albicans virulence genes (UME6, ALS3, SFL2, HWP1 and ECE1) will be address and compared between peritoneal fluid.
Study NCT06116877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported overdenture
Description: mandibular 2-implant retained overdenture of non-modified printable acrylate resins base material with Zirconium oxide nanoparticles
Study NCT06014554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-risk subgroup
Description: Self-managed exercise programme.
Study NCT06014554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium-risk subgroup
Description: Education, goal-orientated mobility programme, and enhanced discharge planning.
Study NCT06014554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-risk subgroup
Description: Education, enhanced assessment, orientation, and goal-orientated activities of daily living training programme.
Study NCT06014554 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Usual care entails physiotherapy and occupational therapy from the day after surgery to the point of discharge, with a focus on discharge planning and sufficient recovery of activities of daily living and mobility for safe return to prefracture residence.
Study NCT05837481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Guided meditation utilizing breath awareness, body scan and visualization techniques
Study NCT05338073 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Known 3Dx Test
Description: Cancer tissue is cultured and treated with a panel of FDA approved chemotherapy and targeted therapies at a range of doses. Cell growth and phenotypes are measured to determine which treatment or treatment combinations would yield the best results for a patient. Test results are compared to actual patient outcomes collected at 3, 6, 9, and 12 months post tissue collection to determine the predictive power of the Known 3Dx Test
Study NCT05444387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb loading
Description: 1 lb. external weight will be wrapped around both wrists during partial body weight support treadmill training. The partial body weight support treadmill training will be given for a maximum of 30 minutes and will finish earlier if the child asked to stop, or if the child stopped stepping. Body weight support will be systematically reduced, walking speed will be progressively increased over the training period, upright standing posture will be emphasized and normal kinematic components of the gait cycle will be facilitated during the training session. The training protocol for the current study will consist of 2 training sessions per weeks with at least one day in between and will last for 6 weeks.
Study NCT04330755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Placebo
Study NCT04330755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Levosimendan
Study NCT04330755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Magnesium Sulfate
Study NCT05225649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Change Intervention
Description: Health coaching sessions; self-monitoring: Fitbit, home scale, and app; personalized health information by mobile health: growth charts and age-specific health behavior information via text message and email; behavior change support by mobile health: family-based health behavior goal setting via chatbot; and usual clinical care.